I can confirm I've contacted management around the same time and got same information as per nwilliam's post.
What they are doing with immunotherapies has been been decided but whatever it is will take some time to announce (legal, due diligence I would assume?) - the immunotherapies program has not been funded from our cash balance outside what has been already budgeted in the last few months - so that should put worries to rest that we will continue to fund a "failure" (although I don't agree, that's what some think)
Questions for Webinar, page-19
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $9.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 2758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |